| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Biological Response Modifiers\' Reputation as \'Wonder Drugs\'Overshadow their Expensive Image The high price of biological response modifiers (BRMs) open excitingopportunities for arthritis drug manufacturers, while their exceptional clinicalperformance offers hope to millions suffering from the disease. Thoughprofitable for manufacturers, the annual BRM treatment cost of over $10,000proves prohibitive for most patients. However, with its ability to curb jointdegeneration and restore normality in motion and functioning, most patients arewilling to take on debts and mortgages in order to meet the high costs that mostmanaged care plans refuse to cover. Significantly lower-priced disease-modifyinganti-rheumatic drugs (DMARDs) are a viable alternative for arthritis patients,but fail to provide the numerous benefits of BRMs. DMARDs also come with severaldrawbacks such as higher toxicity caused by prolonged usage and the inability toreverse the effects of rheumatoid arthritis. Additionally, with the entry oflower-priced and improved drugs that offer convenient dosing and easieradministration, prices of BRMs are likely to fall in order to meet the growingcompetition. This Frost & Sullivan research service analyzes the key drivers andchallenges influencing the U.S. arthritis therapies market. Product and pricingtrends coupled with patient and revenue forecasts enable participants toformulate a structured marketing plan. Product trends and pipeline analysis givean insight into future opportunities in various product segments such as BRMs,DMARDs, COX-2 inhibitors (COX-2s), and other non-steroidal anti-inflammatorydrugs (NSAIDs). Market share and competitive analysis throw light on essentialstrategies to achieve success in the competitive arthritis therapies market. Managed Care Groups Encourage Usage of OTC NSAIDs instead of ExpensivePrescription Drugs "Inexpensive OTC NSAIDs are slowly replacing more efficacious COX-2s dueto managed care initiatives such as higher co-payments and non-coverage ofhigh-priced COX-2s and BRMs until patients have exhausted lower-costalternatives," explains the analyst. Also, OTC NSAIDs are widely availableto control mild-to-moderate arthritis pain before initiating treatment withprescription drugs. However, the ability of COX-2s to alleviate the adversegastrointestinal reactions found in NSAIDs is likely to offset the higher price. Inaccurate diagnosis and treatment of rheumatoid arthritis (RA) is anothermajor issue challenging the arthritis therapies market. Unlike conventionalarthritis, which occurs with advanced age, RA can affect any age group. Timelydiagnosis and treatment with DMARDs and BRMs prevents further jointdeterioration. Though juvenile rheumatology specialists are ideal for RAdiagnosis and treatment, there are only 150 of them in the United States. Thisrestricts the treatment options for children and adolescents with RA. Time-Consuming and Inconvenient BRM Administration Limits Usage "In order to reach their full potential, BRMs must improve theadministration techniques by shifting from injections to more convenient oralformulations that play an important role in attracting patients," says theanalyst. With oral formulations, arthritis patients need not travel longdistances to meet their healthcare practitioner for injections. This willultimately prevent them from skipping or abandoning therapy. AbbottLaboratories\' Humira is a self-administered and easy-to-use injection - asignificant improvement that allows patients to use the drug at theirconvenience. TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- TOTAL U.S. ARTHRITIS THERAPIES MARKET
- Overview
- Introduction
- Methodology
- Market Overview and Definition
- Report Scope and Market Segmentation
- Scope and Segmentation
- Market Engineering Measurement Analysis for Total Market
- Market Demand and Forecasts
- Introduction
- Patient Forecasts
- Pricing Forecasts
- Revenue Forecasts
- Competitive Analysis
- Competitive Landscape
- Market Share
- Industry Issues and Challenges
- Frost and Sullivan Awards
- Company of the Year Award
- Technology Innovation Award
- Research and Development Excellence Award
- BIOLOGICAL RESPONSE MODIFIERS ARTHRITIS THERAPIES MARKET
- Segment Highlights
- Overview
- Introduction
- Biologic Response Modifier Market Engineering Measurement Analysis
- Segment Issues
- Market Demand and Forecasts
- Revenue Analysis and Market Size
- Market Trends
- Factors Affecting Market Growth
- Product Trends
- Pricing Trends
- Competitive Analysis
- Competitive Landscape
- Pipeline Analysis
- Market Share
- NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET
- Segment Highlights
- Overview
- Introduction
- Non-Steroidal Anti-Inflammatory Drug Market Engineering Measurement Analysis
- Segment Issues
- Market Demand and Forecasts
- Revenue Analysis and Market Size
- Market Trends
- Factors Affecting Market Growth
- Product Trends I
- Product Trends II
- Pricing Trends
- Competitive Analysis
- Competitive Landscape
- Pipeline Analysis
- Market Share
- DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS MARKET
- Segment Highlights
- Overview
- Introduction
- Disease Modifying Anti-Rheumatic Drug (DMARD) Arthritis Therapies Market Engineering Measurement Analysis
- Segment Issues
- Market Demand and Forecasts
- Revenue Analysis and Market Size
- Market Trends
- Factors Affecting Market Growth
- Product Trends
- Pricing Trends
- Competitive Analysis
- Competitive Landscape
- Pipeline Analysis
- Market Share
- APPENDIX
- Decision Support Databases
- Arthritis Prevalence
- Population 55 and above
- Biotechnology Companies
- Hospital Beds
- Obese Population
|
